Guggenheim raises Merck stock price target to $171 on Q3 beat

Merck reported Q3 2026 adjusted EPS of $2.49 versus $2.09 expected and revenue of $18.1B versus $17.28B, though roughly $550M of sales benefited from purchase timing. Guggenheim raised its price target to $171 from $170 and lifted its FY2026 EPS estimate to $2.79 from $2.58, while maintaining Buy; it forecast sales of $67.14B, nearly unchanged from $67.13B. Merck also raised and narrowed its full-year outlook, while BofA cited potential 2027 challenges from loss of exclusivity and higher operating expenses.

Analysis

The earnings beat is lower-quality than the headline suggests: management’s reported sales benefit from purchase timing means some revenue may have been pulled forward, creating a potential offset in subsequent quarters rather than durable demand. The key near-term check is whether channel orders and product-level demand remain firm after that timing benefit rolls off. The modest change in Guggenheim’s sales estimate alongside a larger EPS estimate revision also warrants checking the assumptions behind the earnings bridge before treating it as evidence of stronger operating leverage.

Over 1–3 months, raised guidance and pipeline attention can support sentiment, but a single broker’s small target increase is not evidence of a broad valuation reset. Over 6–18 months, the more consequential debate is whether launches and clinical assets can cushion the 2027 loss-of-exclusivity and expense pressures cited by BofA. Pipeline optionality is real but should not be capitalized as proven revenue before trial readouts; setbacks could expose the gap between current earnings and replacement-product contribution.

Contrarian view: the market may be over-crediting the quarter’s beat while underpricing the transition risk, but the article provides no valuation, share-price reaction, or consensus positioning to establish that the stock is mispriced. Avoid a large directional bet until the underlying demand and transition economics are clearer.

Key Decisions for Investors

• Do not chase the post-earnings move solely on the reported beat. For existing holders, retain exposure but require evidence that demand holds after the purchase-timing benefit fades.
• Consider a staged relative-value long in MRK versus a broad healthcare benchmark such as XLV only if MRK stabilizes relative to the benchmark and subsequent reporting confirms underlying product demand; no price entry can be set from the supplied information.
• Track quarterly product-level sales, inventory or channel commentary, updated 2027 guidance, and the expense trajectory. A reversal in demand after the timing benefit or a weaker 2027 outlook would falsify the near-term bullish case.
• Treat the named clinical readouts as event risk, not base-case earnings: verify trial timelines and endpoint results before increasing exposure on pipeline expectations.